New Drug Study for Bladder Cancer

What we are studying

The main purpose of this research study is to evaluate the safety and effectiveness of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer. If you have non-muscle invasive disease with the right disease type (carcinoma in situ or Cis) that failed BCG therapy and was advised to have cystectomy, you may qualify for this trial. If you have muscle invasive disease, you are not eligible for this trial.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnoses with high grade bladder cancer
  • Must have received intrabladder therapy to treat the bladder cancer
  • Have not received full body chemotherapy or radiation

What is involved

  • You will be in the study approximately 2 years and followed for 10 years (via phone calls)
  • Treatment with either the study drug or standard therapy for 6 weeks
  • Blood draws
  • Urine Samples
  • Physical Exams

Contact Information

Study Coordinator
Caroline Ludwig
Email
cludwig@wakehealth.edu
Phone
336-716-5773
Principal Investigator
Dr. Ronald Davis, III

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.